Group 1: Investor Relations Activity - The meeting was categorized as a specific object survey [2] - Participants included representatives from various investment firms and individual investors [2] - The meeting took place on December 10, 2025, at the company's headquarters [2] Group 2: Purpose of the Meeting - The main objective was to understand the company's production and operational status [2]

Group 1: Health Products Business Performance - In the first half of 2025, the health products segment achieved revenue of 3.442 billion CNY, a year-on-year growth of 9.46% [2] - The segment focuses on a full-channel operation strategy, enhancing offline distribution and increasing online promotion efforts [2] - Key products include oral care toothpaste, which maintains a leading position, and hair care brand Yangyuanqing, which continues to grow driven by online sales [2][4] Group 2: Pharmaceutical Business Performance - The pharmaceutical segment reported a main business revenue of 4.751 billion CNY in the first half of 2025, with a year-on-year increase of 10.8% [5] - Sales of Yunnan Baiyao aerosol exceeded 1.453 billion CNY, showing a significant growth of over 20.9% [5] - Other traditional Chinese medicine products also saw notable growth, with sales of Qianling Jianpi Granules surpassing 100 million CNY and Pudilan Anti-inflammatory Tablets nearing 100 million CNY [5] Group 3: Traditional Chinese Medicine Resource Business - The traditional Chinese medicine resource segment generated external revenue of 914 million CNY in the first half of 2025, reflecting a year-on-year growth of approximately 6.3% [6] - The segment implements a "six unifications" operational model to enhance the traditional Chinese medicine industry chain [7] Group 4: R&D and Innovation Progress - The company emphasizes innovation-driven development, focusing on both traditional Chinese medicine and innovative drugs [8] - In the first half of 2025, the company initiated phase III clinical trials for the prostate cancer diagnostic nuclear drug project INR101, with 60 subjects enrolled [9] - The innovative drug project INR102 for prostate cancer treatment received clinical trial approval, and phase I trials have commenced [9] Group 5: Dividend Distribution - For the 2024 fiscal year, the company distributed a cash dividend of 11.85 CNY per 10 shares, totaling approximately 2.164 billion CNY [10] - The total cash dividend for 2024, including special dividends, amounted to 4.279 billion CNY, representing 90.09% of the net profit attributable to shareholders [10] - In the first half of 2025, the company distributed a cash dividend of 10.19 CNY per 10 shares, totaling 1.818 billion CNY, which accounted for 50.05% of the net profit for that period [10]

Group 1: Investor Relations Activity - The meeting was categorized as a specific object survey [2] - Participants included individual investors: Huang Kaiwei, Li Minggui, Chen Jiahe, Guo Hao, and Cui Weigang [2] - The meeting took place on December 10, 2025, at the Group's headquarters [2] Group 2: Company Overview - The main purpose of the investor relations activity was to understand the company's production and operational status [2] - Company representatives included Zhang Yu, Yang Kexin, and Yu Yang from the investor relations management team [2]

Group 1: Pharmaceutical Business Performance - In the first half of 2025, the pharmaceutical business group achieved a main business revenue of 4.751 billion yuan, a year-on-year increase of 10.8% [2] - Sales revenue of Yunnan Baiyao aerosol exceeded 1.453 billion yuan, with a significant year-on-year growth of over 20.9% [2] - Other core products, including Yunnan Baiyao plaster and capsules, also saw notable growth, contributing to the overall revenue increase [2] - Plant-based products, such as Qixue Kang oral liquid, reached sales of 202 million yuan, with a year-on-year growth of approximately 116.2% [2] Group 2: Health Product Channel Development - The company has established a comprehensive national sales team for health products, maintaining a leading market share in Yunnan Baiyao toothpaste [4] - Continuous optimization of the entire channel has strengthened traditional offline advantages while also focusing on emerging retail formats like instant retail and community group buying [4] Group 3: Traditional Chinese Medicine Cultivation Achievements - The company has implemented a precise research and transformation model for seed innovation, achieving coverage of ten major Yunnan medicinal sources [5] - The area of high-quality seed promotion has reached 90% of the annual target, with significant progress in the construction of "Yun Medicine Seed Valley" [5] - Over 7,000 acres of GAP management have been added for various medicinal herbs, integrating low-altitude economy and IoT technology [5] Group 4: Online Sales Performance - The pharmaceutical business group has expanded its online market, with O2O sales increasing by over 20% year-on-year [6] - During the 2025 "618" shopping festival, the company achieved a GMV of 254 million yuan through e-commerce platforms, attracting 48.45 million visitors [7] - Yunnan Baiyao toothpaste maintained the top market share in the domestic channel, while Yangyuan Qing ranked first in Tmall for anti-hair loss shampoo [7] Group 5: Nuclear Medicine Research Progress - The INR101 diagnostic nuclear medicine project has initiated Phase III clinical trials, with 32 research centers established and 60 subjects enrolled [8] - The INR102 therapeutic nuclear medicine project has received a clinical trial notification, with Phase I trials underway and 12 patients enrolled [8]

点击上图▲立即收听 " 2020 年，大众的健康消费行为以 ' 朋克养生 ' 为主，到 2025 年已然进阶成 ' 悦养身心 ' ，短短四个字，情绪在如今消费决策中的权重不言而喻。 " 文 /巴九灵（微信公众号：吴晓波频道） 在社媒平台上，一种新的社交语言在兴起。 "今天吃逍遥丸了吗""气血不足，六味地黄丸安排上""普瑞巴林救我狗命，焦虑发作时它比男朋友管用"…… 图 源：小 红书 这些本该出现在医院处方笺上的药品，如今成了年轻人的情绪代餐、身份标签甚至是社交货币。 据CBNData调研数据，在习惯、情绪与环境的三重夹击下，88%的年轻人开始主动用药品、健康消费品进行"自救式健康管理"。 健康，成为了价值观、世界观、人生观之外的"第四观"，自嘲"脆皮青年"的年轻人正在用一套全新的逻辑，认真管理自己的身体。 那么，"身体脆一点，情绪更脆一点"的年轻人钱包里，究竟藏着一张怎样的情绪账单？ 最近，盖洛普与世界卫生峰会联合发布的《2025年世界情绪健康状况》报告显示，2024年有39%的成年人坦言自己经历着大量担忧，37%的人感 到压力重重，其次还有身体疼痛（32%）、悲伤（26%）和愤怒（22%）。而且，这些指标明 ...

Core Viewpoint - The report highlights the growth of industrial enterprises in Yunnan Province, indicating a positive trend in the industrial sector with a year-on-year increase in the number of enterprises [1]. Group 1: Industrial Enterprises in Yunnan - As of January to October 2025, the number of industrial enterprises in Yunnan Province reached 5,670, an increase of 211 compared to the same period last year, representing a year-on-year growth of 3.87% [1]. - The industrial enterprises in Yunnan account for 1.08% of the total number of industrial enterprises in the country [1]. Group 2: Related Companies - The report mentions several listed companies in Yunnan, including Yun Aluminum Co., Yunnan Copper Co., and others, indicating a diverse industrial landscape [1]. - The companies listed span various sectors, including mining, pharmaceuticals, and energy, reflecting the broad industrial base in Yunnan [1]. Group 3: Research and Consulting - The report is published by Zhiyan Consulting, a leading industry consulting firm in China, known for its in-depth industry research and comprehensive consulting services [1]. - Zhiyan Consulting has been active in the industry research field for over a decade, providing valuable insights and solutions for investment decisions [1].

Group 1 - The core viewpoint of the report indicates that the Chinese fast-moving consumer goods (FMCG) market is stabilizing, with a 1.3% year-on-year sales growth in the first three quarters of 2025, driven by a 3.8% increase in volume and a 2.4% decrease in average price [14][17][18] - Lower-tier cities (third to fifth tier) are identified as the main growth engine, contributing 80% of market growth, supported by urbanization, brand penetration strategies, and new retail channels [14][26][47] - The performance of different categories shows divergence, with packaged food and household care leading growth at 3.4% and 3.3% respectively, while the beverage category declined by 1.1% due to price competition and market shifts [29][39][46] Group 2 - The "consumption substitution" trend continues in 2025 but is slowing down, with average price declines narrowing from 3.4% in 2024 to 2.4% in 2025, indicating consumers are weighing quality against price [2][15][49] - New retail channels are experiencing structural changes, with traditional offline channels shrinking while warehouse membership stores, snack collection stores, and discount stores are expanding rapidly, with growth rates of 40%, 51%, and 92% respectively [2][59][60] - E-commerce channels are also growing at 7%, with platforms like Douyin and Pinduoduo becoming major drivers, accounting for over 40% of total FMCG e-commerce sales [2][59] Group 3 - The report highlights that the FMCG market is entering a new phase driven by demand, where brands must adapt to fragmented and polarized retail landscapes to seize growth opportunities [58] - The average selling price in the FMCG market is stabilizing, with promotional contributions to sales decreasing from 24.1% to 23.0%, reflecting a shift in consumer behavior towards quality and price balance [18][49] - The report emphasizes the importance of understanding consumer needs and adapting product offerings and pricing strategies to achieve sustainable growth in the evolving market [2][58]

Group 1 - Yunnan Baiyao has undergone significant management changes, with Dong Ming stepping down as the legal representative and Wang Minghui resigning as chairman, replaced by Zhang Wenxue [1][2] - The registered capital of Yunnan Baiyao has increased from approximately 1.04 billion RMB to about 1.78 billion RMB [1][2] - The company was established in November 1993 and operates in various sectors including chemical raw materials, traditional Chinese medicine, and medical devices [1][3] Group 2 - The company is jointly held by Yunnan Provincial State-owned Assets Management Company, Xinhua Duhua Industrial Group Co., Ltd., and Yunnan Hehe Group Co., Ltd. [1][4] - The 11th Board of Directors meeting announced Zhang Wenxue as chairman and Dong Ming as vice chairman for a term of three years [1][2] - The company has a diverse business scope that includes sales of pharmaceuticals, medical devices, and technology consulting services [1][3]

Core Viewpoint - Two sides of the needle are expanding production, focusing on hotel toothpaste and slippers, but despite maintaining a leading market share, profitability has significantly declined [1][11]. Group 1: Company Strategy and Performance - The company plans to invest 68.85 million yuan to expand its production base for functional oral care products, including toothpaste and hotel slippers [2]. - The current production capacity for hotel toothpaste is nearly at full capacity, with a utilization rate of 90.21% for the hotel toothpaste workshop, while the household toothpaste factory has a much lower utilization rate of 34.5% [4][5]. - The average selling price of hotel toothpaste has remained low, around 8 cents per unit, which has not changed significantly over the past decade [1][12]. Group 2: Market Position and Competition - Despite losing market share in the household toothpaste segment, the company remains a leader in the hotel channel, with hotel toothpaste sales increasing from 980 million units in 2015 to nearly 1.6 billion units in 2024 [8][9]. - The company faces intense competition as other brands, such as Yunnan Baiyao and Shuke, are also entering the hotel market, which may further pressure profit margins [27]. - The gross margin for hotel toothpaste is low, with the company lacking significant negotiation power against major hotel groups, leading to reduced profitability [11][15]. Group 3: Historical Context and Challenges - The company was once a dominant player in the household toothpaste market, achieving a market share of 16.3% in the early 2000s, but has since struggled to maintain its position [7][18]. - The shift towards diversification in various sectors has diluted focus on the core toothpaste business, contributing to declining performance in the competitive landscape [17]. - The household toothpaste sales have drastically decreased from 50.84 million units in 2015 to 32.59 million units in 2024, indicating a significant loss of market presence [19][22].

Core Viewpoint - Two sides needle is expanding production focused on hotel toothpaste and slippers, but despite maintaining a leading market share, its profitability has significantly declined [1][7][8] Group 1: Business Expansion and Production Capacity - Two sides needle plans to invest 68.85 million yuan to expand its production base for functional oral care products, including a toothpaste production workshop and a hotel slipper production workshop [2] - The company needs to increase hotel toothpaste production capacity as its original design capacity is nearly fully utilized [2][4] - The annual production capacity for hotel supplies is 1.9 billion tubes, with a utilization rate of 90.21%, while the household toothpaste production capacity is only 34.5% utilized [4] Group 2: Market Position and Sales Performance - Two sides needle was once a leading brand in the household toothpaste market but has lost significant market share, with household toothpaste sales dropping from 50.84 million tubes in 2015 to 32.59 million tubes in 2024 [13][16] - The average selling price of hotel toothpaste has remained low, with the current price around 8 cents per tube, reflecting a lack of pricing power against major hotel groups [9][11] - The company’s revenue from household toothpaste was 4.43 billion yuan in 2003, but it has struggled to maintain profitability in the hotel channel despite high sales volumes [6][12] Group 3: Profitability Challenges - The gross margin for hotel toothpaste is low, with the company facing increasing pressure from hotel groups that demand lower prices, leading to a situation where sales grow but profits do not [8][11][30] - The gross profit margin for the company’s daily chemical products has only slightly improved from 13.65% in 2011 to 13.84% in 2024, indicating stagnant profitability [8] - Other brands like Yunnan Baiyao and Cold Acid Spirit are also entering the hotel market, increasing competition and further squeezing margins for traditional brands like Two Sides Needle [23][30] Group 4: Industry Trends and Competitive Landscape - The hotel supply chain is experiencing pressure from rising manufacturing costs, which affects profitability across the industry [24][30] - Traditional consumable brands are facing challenges due to product homogeneity and overcapacity, leading to price competition [30][31] - The emergence of alternative products, such as mouthwash, is diverting customers away from traditional hotel toothpaste, necessitating innovation and differentiation in product offerings [31][32]